Which antibiotic is safer for blood infections? new study digs into Real-World data

NCT ID NCT07186894

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looks back at medical records of about 5,000 people with a serious bloodstream infection caused by a common bacterium. Researchers compare two antibiotic treatments to see which one leads to better survival and fewer side effects. The goal is to find out if a newer option (cefazolin) is as good as or better than the standard penicillins.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

cefazolin and antistaphylococcal penicillins (flucloxacillin, cloxacillin, oxacillin, nafcillin, dicloxacillin)

What this could lead to

If cefazolin proves as effective as standard penicillins with fewer side effects, it could become a preferred treatment for this serious infection.

What could go wrong

This is a retrospective study using existing medical records, not a controlled experiment, so results may be less reliable. Differences in patient groups could bias the findings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTERIEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease with sepsis Infections methicillin-susceptible staphylococcus aureus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.